Protocol Ledger

NCT05043922 · Phase II · ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Interventional Phase II clinical trial protocol NCT05043922 sponsored by Haihe Biopharma Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-11 Enrollment: 93 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05043922
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)93 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05043922
Protocol FieldVerified Registry Value
NCT IdentifierNCT05043922
Consolidated Lead SponsorHaihe Biopharma Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment93 participants (ACTUAL)
Registered Start Date2021-10-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI